report secondary Sjögren’s syndrome to be associated with an increased risk of organ damage in SLE.

Funding Source(s): This work was supported by grants from the Swedish Rheumatism Association, the County Council of Östergötland, the Swedish Society of Medicine, the King Gustaf Vs 80 year anniversary foundation and the King Gustaf V and Queen Victorias Freemasons foundation.

Background SLE patients are characterized by a lipid metabolism dysregulation. Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates cholesterol metabolism through low-density-lipoprotein (LDL) receptor degradation. PCSK9 has been linked to cardiovascular risk (CVR) in general population. The purpose of this study is to examine whether PCSK9 levels are related to disease activity, damage and severity scores; abnormalities in the lipid profile; and the subclinical atherosclerosis that occur in SLE patients.

Methods Cross-sectional study that encompasses 195 SLE patients. PCSK9 and lipoproteins serum concentrations were assessed. Activity (SLEDAI), severity (Katz) and damage (SLICC) index scores, and carotid ultrasound sonography were evaluated. A multivariable analysis was performed to evaluate the association of PCSK9 with SLE related dyslipidemia, subclinical atherosclerosis and activity/damage status.

Results In the univariate analysis, body mass index, waist circumference, traditional CVR factors and triglycerides were related with PCSK9 serum levels. On the contrary, HDL cholesterol and apolipoprotein A levels showed a negative association. LDL cholesterol exhibited a trend to a negative association (beta coeff. –0.30, 95% CI –0.67–0.07, p=0.11). Carotid plaques and cIMT were not associated with PCSK9 levels although a trend was observed. Patients with longer disease duration (beta coeff. 1.25, 95% CI 0.15–2.35, p=0.026) and higher C reactive protein levels (beta coeff. 1.42, 95% CI 0.61–2.22, p=0.00) disclosed higher PCSK9 levels. Prednisone intake was positively associated with PCSK9 (beta coeff. 0.01, 95% CI 35.48–56.56, p=0.001), and patients that were taking any DMARD or hydroxychloroquine disclosed significant lower levels of PCSK9 (beta coeff. –2.71, 95% CI –5.45––1.32, p=0.040) and beta coeff. –39.21, 95% CI –62.21––16.21, p=0.001 respectively). Higher values of SLICC (beta coeff. 9.66, 95% CI 4.47–14.84, p=0.00) and patients that were in the high/very high SLEDAI activity category (beta coeff. 62.98 95% CI 18.10–107.86, p=0.006) disclosed significant higher values of PCSK9. When multivariate analysis was performed these positive associations with both SLICC and SLEDAI and the use of prednisone were maintained, as well as negative associations with LDL levels and the use of hydroxychloroquine.

Conclusions PCSK9 serum levels are independently related to SLE activity and damage scores. This would imply that the mechanisms leading to lipid metabolism dysregulation in SLE patients may be mediated or be a consequence of PCSK9.

Background Systemic lupus erythematosus (SLE) is commonly treated with broad immunosuppression, including cyclophosphamide. Use of this agent can result in ovarian toxicity leading to premature menopause. Ovarian failure is associated with concomitant hypothyroidism. We hypothesized that hypothyroidism might be a marker for ovarian autoimmunity because organ-specific autoimmune diseases tend to occur together. We undertook this study to determine whether anti-ovarian antibodies are associated with premature ovarian failure among SLE women who received cyclophosphamide.

Methods All SLE women with a history of cyclophosphamide therapy were identified in the Lupus Registry and Repository (LFRR). All subjects were shown to meet the revised ACR classification criteria. Premature menopause was defined as spontaneous lack of menstrual periods prior to age 45. Anti-ovarian antibodies were measured by ELISA (Anti-Ovarian Ab ELISA, IBL, Minneapolis, catalog # IB9184). Data were analyzed by Students T test and chi square testing. The protocol received ethical approval from the University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation IRBs.

Results Among ~3000 SLE women enrolled in the LFRR who had received cyclophosphamide, we found 169 with menopause before age 45 along with 73 who underwent menopause after age 45 and 16 patients over age 45 who were still having menstrual periods at the time of evaluation. Thus, there were a total of 89 SLE women who did not have premature menopause. Mean anti-ovarian antibodies in the 169 with premature ovarian failure was 16.2 units (SD=20.3), while the mean among those without premature menopause was 17.4 units (SD=21.7). These values were not statistically different between the groups. 11 of 169 (6.5%) prematurely menopausal SLE women had a positive result and 8 of 89 (8.9%) without premature menopause were positive (2=0.53, p=0.46, OR=1.02 (95% CI 0.95–1.1).

Conclusions Anti-ovarian antibodies were present at low levels (~10% positivity) among women with SLE. However, the presence of these antibodies was not related to premature ovarian failure after cyclophosphamide.